1. Home
  2. KZIA

as 04-25-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Founded: 1994 Country:
Australia
Australia
Employees: N/A City: NEW SOUTH WALES 2113
Market Cap: 860.8K IPO Year: 1999
Target Price: $57.50 AVG Volume (30 days): 30.1K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -33.88 EPS Growth: N/A
52 Week Low/High: $2.86 - $79.00 Next Earning Date: 05-02-2025
Revenue: $1,655,324 Revenue Growth: 248000.00%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

KZIA Daily Stock ML Predictions

Compare KZIA vs Leading Stocks

Share on Social Networks:

Similar to KZIA Stocks: